RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin
Status:
Unknown status
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare two therapeutical strategies concerning the combination
therapy (peginterferon alfa-2a and ribavirin) in naïve patients with chronic hepatitis C of
genotype 1. "Reference" strategy corresponding to standards of care recommended by the French
consensus conference versus "Test" strategy corresponding to adaptation strategy of ribavirin
dose during the first week according to AUC (area under the curve) of ribavirin plasmatic
concentration after the first intake (Day 0) of 600 mg